Comparative Pharmacology
Head-to-head clinical analysis: HEDULIN versus PANWARFIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEDULIN versus PANWARFIN.
HEDULIN vs PANWARFIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HEDULIN (phenindione) is an anticoagulant that inhibits vitamin K-dependent synthesis of coagulation factors II, VII, IX, and X in the liver, thereby reducing thrombus formation.
Anticoagulant that inhibits vitamin K epoxide reductase, thereby decreasing hepatic synthesis of vitamin K-dependent coagulation factors II, VII, IX, and X.
Oral, 200-400 mg initially, then 100-200 mg every 6-12 hours; maximum daily dose 1200 mg.
5 mg orally once daily, adjusted to maintain INR 2-3.
None Documented
None Documented
Terminal elimination half-life is 18-24 hours in patients with normal renal function; may be prolonged to 30-40 hours in renal impairment, necessitating dose adjustment.
Terminal elimination half-life is 20-60 hours (mean ~40 hours). Clinically, the longer half-life allows for once-daily dosing and steady-state is achieved in 5-7 days; anticoagulant effect may persist for 2-5 days after discontinuation due to depletion of vitamin K-dependent clotting factors.
Renal excretion of unchanged drug accounts for approximately 70% of elimination; the remainder is metabolized hepatically and excreted in feces via bile.
Primarily renal as inactive metabolites; 60-92% of a dose is excreted in urine, with about 50% as the 7-hydroxywarfarin metabolite and the remainder as other metabolites. Biliary/fecal elimination accounts for approximately 10-20%.
Category C
Category C
Anticoagulant
Anticoagulant